Concerns Surrounding Wanbangde Pharmaceutical Holding Group's (SZSE:002082) Performance
Wan Bond: 2024 Semi-Annual Report
Wan Bond: 2024 Semi-Annual Report Summary
wanbangde pharmaceutical holding group (002082.SZ) released its performance for the first half of the year, with a net income of 37.7041 million yuan, an increase of 19.36%.
Wanbangde Pharmaceutical Holding Group (002082.SZ) released its 2024 semi-annual report. During the reporting period, the company achieved revenue of 7...
Wanbangde Pharmaceutical Holding Group (002082.SZ): Net income in the first half of the year was 37.7 million yuan, a year-on-year increase of 19.36%.
On August 28, Wanbangde (002082.SZ) released its semi-annual report, with a revenue of 0.75 billion yuan, a year-on-year increase of 1.93%, a net income of 37.7 million yuan, a year-on-year increase of 19.36%, a non-GAAP net income of 18.07 million yuan, a year-on-year decrease of 4.53%, and a basic earnings per share of 0.0611 yuan.
Wanbangde Pharmaceutical's Subsidiary to Get 54 Million Yuan for Relocation
Wanbangde Pharmaceutical Holding Group (002082.SZ): Kangci Medical has signed a compensation agreement for the acquisition of houses on state-owned land, involving a compensation of 53.9072 million yuan.
On August 12th, Gelunhui reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that due to the need for organic renewal and improvement of land in the Jianghe Economic Corridor in Jiangshan City, Zhejiang, the Jiangshan Economic Development Zone Management Committee, represented by Shanhai Construction Investment Co., Ltd. (hereinafter referred to as "Shanhai Construction"), will expropriate the land, buildings and ancillary facilities, equipment and other assets of Zhejiang Kangci Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, located at No. 20 Huiyuan Road, Jiangshan Economic Development Zone, Shanhai Cooperation Zone, Jiangshan City ("this expropriation").
Wanbangde Pharmaceutical Holding Group (002082.SZ): Orphan drugs and rare disease drugs certified by the FDA have not yet entered the clinical trial stage.
On July 31st, Gleaming Healthcare (002082.SZ) stated on the investor interactive platform that the company is committed to bringing better clinical benefits to global patients. The orphan drugs and rare pediatric disease recognition by the US FDA have laid a good regulatory and registration foundation for the international development of products. At present, the FDA's new drug application (IND) is being processed normally and clinical trials have not yet begun.
Wanbangde Pharmaceutical Holding Group (002082.SZ) equity distribution in 2023: 0.8 yuan per 10 shares.
Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that their annual equity distribution plan for 2023 is as follows: based on the company's existing total share capital after deducting repurchased shares, every 10 shareholders will receive RMB 0.8 in cash (including taxes). The registration day for equity distribution is July 10, 2024, and the ex-rights and ex-dividend day is July 11, 2024.
Wan Bond (002082.SZ): Huperzine A's indication for neonatal hypoxic ischemic encephalopathy was certified as an orphan drug by the US FDA
Wanbond (002082.SZ) issued an announcement. Wanbond Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, announced in 202...
Wan Bond (002082.SZ): Zhao Shouming, one of the actual controllers, completed a 1.188% increase in shares
Gelonghui, May 24 | Wan Bond (002082.SZ) announced that as of the announcement disclosure date, Mr. Zhao Shouming, one of the actual controllers, chairman and general manager of the company, had increased his holdings of the company's shares by 7,326,900 shares through centralized bidding transactions on the Shenzhen Stock Exchange, accounting for 1.1881% of the company's current total share capital. The amount of increase in holdings was 32.777.78 million yuan. The implementation of this share increase plan was completed.
Chairman Wan Bond (002082.SZ) increased his total share holdings by 1.19%
Wan Bond (002082.SZ) issued an announcement. As of May 8, 2024, the time for this holdings increase plan has passed...
US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A
Wanbangde Pharmaceutical Holding Group Co., Ltd.'s (SZSE:002082) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Wan Bond (002082.SZ): Net profit of 288.385 million yuan in the first quarter increased 5.49% year-on-year
On April 29, Ge Longhui (002082.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 429 million yuan, up 11.41% year on year; net profit attributable to shareholders of listed companies was 288.385 million yuan, up 5.49% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 14.097 million yuan, down 43.19% year on year; basic earnings per share were 0.0466 yuan.
Wan Bond (002082.SZ) net profit due to mother in 2023 fell 47.23% to 49.089 million yuan and plans to pay 10 0.8 yuan
On April 25, Gelonghui (002082.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 1,542 billion yuan, a year-on-year decrease of 13.69%, and net profit to mother of 47.23%. Among them, the pharmaceutical manufacturing sector achieved operating revenue of 1,054 billion yuan, a year-on-year decrease of 23.71%; net profit to mother was 140 million yuan, a year-on-year decrease of 53.15%; the medical device sector achieved operating revenue of 495 million yuan, 10,000 yuan up 21.45% year on year, and net profit to mother of 578.161,000 yuan
Wanbond (002082.SZ): Wanbond Pharmaceuticals passed the Korea MFDS on-site inspection
Gelonghui, April 10 | Wanbond (002082.SZ) announced that Wanbond Pharmaceutical Group Co., Ltd. (“Wanbond Pharmaceutical”), a wholly-owned subsidiary of the company, underwent regular on-site inspections by the Ministry of Food and Drug Safety (MFDS) of the Korean Ministry of Food and Drug Safety (MFDS) for the registration of biphenyl diester APIs in Korea on March 5-7, 2024. The scope of inspection covers quality, production, equipment and facilities, laboratory control, materials and packaging labeling systems. Recently, Wanbond Pharmaceutical received a notification letter from South Korea's MFDS “Field Inspection Results for Overseas Drug Manufacturers”. This time, it successfully passed the Korea MFDS on-site inspection, indicating Wanbond Pharmaceutical raw materials
Wan Bond (002082.SZ): Zhao Shouming increased his total shares by 1.1881%
Gelonghui, March 6 | Wan Bond (002082.SZ) announced that as of the disclosure date of this announcement, Mr. Zhao Shouming had increased his holdings of the company's shares by 7,326,900 shares through centralized bidding transactions on the Shenzhen Stock Exchange, accounting for 1.1881% of the company's total share capital, with an increase of 32.7798 million yuan. In total, Mr. Zhao Shouming and his co-actors held 50.0653% of the company's shares.
Wan Bond (002082.SZ): Wan Bond Investment plans to participate in Aohan Ruikang
Gelonghui, March 5 | According to the pharmaceutical health industry development strategy, the company plans to participate in the Nanjing Aohan Ruikang Equity Investment Partnership (Limited Partnership) (“Ao Han) Investment Management Co., Ltd.” (“Wan Bond Investment”), a wholly-owned subsidiary of the company, to make full use of the professional resources of professional investment institutions and their investment management advantages to promote the company's long-term development, the company's wholly-owned subsidiary Wanbond (Hangzhou) Investment Management Co., Ltd. (“Wanbond Investment”) plans to participate in the Nanjing Aohan Investment Management Co., Ltd. (“Shanghai Aohan Investment”)”), The investment direction of the investment fund is
Wan Bond (002082.SZ) plans to spend no more than 300 million yuan to subscribe to the Aohan Ruikang Fund share to invest in the pharmaceutical and health industry
Wan Bond (002082.SZ) announced that according to the pharmaceutical and health industry development strategy, in order to make full use of professional investment...
No Data
No Data